EndoChoice Holdings Inc

EndoChoice — Investor Presentation (November 2015)

38 slides from EndoChoice's investor presentation, Nov 5, 2015

  1. Slide 1: A Platform GI Company

    Mark Gilreath Founder & CEO David Gill Chief Financial Officer A Platform GI Company November 2015 Exhibit 99.1

  2. Slide 2: Safe Harbor

    Safe Harbor This presentation contains forward‐looking statements. You should not rely upon forward‐looking statements as predictions of future events. All statements other than statements of historical facts contained in this presentation, including information concerning our possible or assumed fu

  3. Slide 3: The Company

    Q | The Company QENDCCHOICE

  4. Slide 4: EndoChoice: A Platform Company Serving the GI Caregiver

    EndoChoice: A Platform Company Serving the GI Caregiver

  5. Slide 5: EndoChoice at a Glance

    Platform GI Company Differentiated Tech $6B Market Proven Track Record + + Platform company focused across entire GI procedure cycle Fuse® detected 69% more pre-cancerous polyps, Cost effective technology $6B Global GI market, growing annually at 7% Management team with proven track record 2,500+ es

  6. Slide 6: Management Strength

    Management Strength Mark Gilreath Founder & CEO 23 years experience in GI market Former President, Americas Given Imaging, maker of PillCam technology Transformed Given Imaging from pre-revenue start-up to $120M NASDAQ-listed company David Gill Chief Financial Officer 20 years experience in medical

  7. Slide 7: Scalable Infrastructure

    >2,500 Customers in the US >Distributors in 30 countries 450 Employees Worldwide 285 100 65 Scalable Infrastructure Global Headquarters Alpharetta, GA USA West Coast Distribution Reno, NV USA Imaging Services Nashville, TN USA International Headquarters & Manufacturing Hamburg, Germany Research & De

  8. Slide 8: GI Market Opportunity

    e) Gl Market Opportunity QENDCCHOICE

  9. Slide 9: EndoChoice Growth Drivers

    Imaging Devices Pathology Infection Control Source: Markets & Markets, Endoscopy Equipment, Global Forecasts to 2018; The U.S. Anatomic Pathology Market, Forecast & Trends 2014-15; Annual Reports and EndoChoice Internal Estimates Note: Devices do not include ERCP and EUS opportunity EndoChoice Growt

  10. Slide 10: Attractive Oncology End Markets

    Attractive Oncology End Markets Gastric and esophageal cancer GERD monitoring Abdominal pain diagnosis National Colorectal Cancer Roundtable goal: Increase colorectal cancer screening rates from ~60% currently to 80% by 2018 Colorectal cancer screening – highly preventable if detected early ~1.4 mil

  11. Slide 11: A World of Opportunity

    Dilation Visualization Airway Personal Protection Inventory Mgt Diagnostic Tests Luminal Access Tissue Acquisition Patient Monitoring Luminal Patency Data Management EndoKits Preparation Suction Patient Service Hemostasis Cleaning Retrieval Transport Mobility Quality Measures Infection Risk A World

  12. Slide 12: Fragmented GI Community

    Fragmented GI Community Setup OME. MSKESSON “Keanna Scope Repair Equipment OLymPuS (we OLYMPUS PENTAX FUJIFILM GlyeN,, OeAreX ERBE Gl Clean & Disinfect Procedure Devices Ruwior CMetrex wears Cycle RET Rc aoa COVIDIEN Transport Pathology cD «smu LabCorp BACARS Poros Pre-Clean es RuHoFd cyexud) Ciletr

  13. Slide 13: EndoChoice Platform

    EndoChoice Platform Q Setup Cadi & Scope Repair Be Qe Clean & Disinfect Ztal WA Q Transport en © gon nd =a Pre-Clean Q Equipment i Q Devices AMA Q Pathology QENDCCHOICE Fy <a 2)

  14. Slide 14: Proven Track Record in GI Innovation

    Proven Track Record in GI Innovation ASP Range of $2 to $220,000

  15. Slide 15: Three Growth Engines

    Fuse® system Scope repair services and accessories Infection control products Therapeutic devices (forceps, snares, injection needles, retrieval) Advanced technology combined with highly trained GI pathologists Customized solutions to enhance care Total Imaging Single Use Products Pathology 2014 Rev

  16. Slide 16: Fuse Full Spectrum Endoscopy

    Fuse® Full Spectrum Endoscopy

  17. Slide 17: Major Video Endoscopy Players

    Major Video Endoscopy Players GI Flexible Endoscopy Surgical Endoscopy

  18. Slide 18: A New Standard in GI Imaging

    A New Standard in Gl Imaging QENDCCHOICE

  19. Slide 19: Fuse Enabling Technologies

    LEDs Fuse® Enabling Technologies Integrating LEDs and Multiple Imagers 3 Imagers Light Guides 1 Imager Traditional Colonoscope Fuse Colonoscope

  20. Slide 20: Limited View with 170° Colonoscopy

    Limited View with 170° Colonoscopy

  21. Slide 21: 330° Field of View with Fuse

    330° Field of View with Fuse® QUENDCCHOICE ———_ a O J = < te QENDCCHOICE 2

  22. Slide 22: Compelling Clinical and Cost-Effectiveness Data

    Compelling Clinical and Cost-Effectiveness Data Sources: Gralnek IM, Siersema PD, Rex DK, et al. Standard forward-viewing colonoscopy versus full-spectrum endoscopy: an international, multicentre, randomised, tandem colonoscopy trial. The Lancet Oncology 2014; 15: 353-60. Hassan, et al, Cost-effecti

  23. Slide 23: Speed of Innovation

    Speed of Innovation 4K Single Monitor Locking Lever Brighter Image, Improved Quality StrataFlex Insertion Tube 2013 – Generation 1 2015 – Generation 2

  24. Slide 24: Fuse Adds Value for All Stakeholders

    Physician Significant GI advance Differentiated practice, more procedures Payor Cost saving technology Addressing problem of interval cancer Hospital/ASC Differentiated technology Marketing advantage Patient Reduced fear of missed polyps Increased confidence in negative exam Fuse® Adds Value for All

  25. Slide 25: Driving Commercial Success

    e) Driving Commercial Success QENDCCHOICE

  26. Slide 26: Expanding Global Sales Presence

    Global Headquarters Alpharetta, GA USA International Headquarters Hamburg, Germany 50 è 70 Direct sales territories in the US 30 International markets via distributors Expanding Global Sales Presence

  27. Slide 27: US Expansion Combined with Optimization

    US Expansion Combined with Optimization Expansion – Q4 2015 Imaging SUP Pathology 70 Territory Managers December 2014 December 2013 Since December 2013 (pre-Fuse), sales force is expanding from 50 reps to 90 total sales reps and 8 Regions to 11. With the new expansion, Territory Managers (TMs) sell

  28. Slide 28: Established Reimbursement

    Established Reimbursement Reimbursement Medicare Nat’l Avg Coding Description ASC Hospital G0121 Colonoscopy, Screening $569 $864 CPT 45385 Colonoscopy, with Polypectomy $747 $1,103 CPT 43235 EGD, (Gastroscopy) $545 $880 Pathology billed separately. Collections average $100 per specimen. Note: All f

  29. Slide 29: Practice Marketing Tools

    Practice Marketing Tools Colon ME Health Alert Bd | Spectrum Endoscopy Nt Fe rau 08 (Click Here WCamegie Hill | ASE QENDCCHOICE Ray = - ~<qi7 >=

  30. Slide 30: Strong Financial Profile

    Q Strong Financial Profile QENDCCHOICE

  31. Slide 31: Consistent Revenue Growth Provides Foundation for Future

    Consistent Revenue Growth Provides Foundation for Future First sales of Fuse® Generation 1 in late 2013 to gain experience; Started deliveries of Gen 2 in Q2 2015

  32. Slide 32: Fuse Addresses $1 Billion Annual Opportunity

    Fuse® Addresses $1 Billion Annual Opportunity ASPs U.S. – $205,000 ROW – $110,000 1,800 ASCs and 5,200 hospitals in the U.S. averaging 2+ systems each

  33. Slide 33: 44% Average Quarterly Growth Fuse Sales

    44% Average Quarterly Growth Fuse® Sales Installed base now exceeds 100 systems 81% of Fuse customers buy our Single Use Products

  34. Slide 34: Two Growth Drivers for Single-Use Products

    Two Growth Drivers for Single-Use Products: Customer count and Average Monthly Order (AMO) Presence in 2,500 GI departments (1/3 of U.S. market) will drive penetration 65% of our SUP customers buy multiple products SUP AMO for Fuse customers grew from $3,674 and $3,747 in Q3’15

  35. Slide 35: Life Cycle Revenue Potential Per new ASC customer

    Life Cycle Revenue Potential Per new ASC customer 2 Room ASC Revenue Value One Time Sale Fuse Video System, 2 Rooms $440,000 Recurring Revenue Devices $160,000 EndoKits $160,000 Endoscope Reprocessing $80,000 Endoscope Service $120,000 Pathology Billing $2,000,000 Total Recurring Revenue Over 5 Year

  36. Slide 36: Path To Gross Margin Improvement

    Path To Gross Margin Improvement – Gain Scale in Fuse Manufacturing Target Current State Fixed Manufacturing Overhead Units Produced Fixed OH per system Direct Materials per system Direct Labor per system Total Costs/System US ASP/System Gross Margin% $11.5M 100 $115 $75 $15 $205 $205 0% $15.0M 500

  37. Slide 37: Path To Profitability

    Path To Profitability Longer Term Operating Goals Gross margin expansion will be driven by: Spreading fixed manufacturing costs over higher unit volumes Design programs to reduce parts and improve manufacturability Greater purchasing leverage with vendors on higher volumes Long Term Goals Gross Marg

  38. Slide 38: Strong Capitalization

    Strong Capitalization (in millions) September 30, 2015 Actual Cash $102.7 Long-term debt $42.6 Net equity $110.1 Refinanced debt in June 2015 – lowering interest rate and deferring principal payments to January 2018 $15 Mil available under revolver

EndoChoice Holdings — Investor Presentation (November 2015) on 6ix